옵티미 헬스(OPTH) 주가 전망 및 기업 분석 - PER·배당·실적·목표주가·RSI·MACD

OPTH

Optimi Health Corp

7월 27일 4:00 PM ET (한국 7/28 05:00)

$4.92

+0.24 ▲ +5.13%

옵티미 헬스(OPTH) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시가총액

$28M

스몰캡

P/E

배당수익률

없음

52주 위치

31%

저점 +58% · 고점 -44%

애널리스트

C+

Fundamental health

vs. Drug Manufacturers - Specialty & Generic 초소형주· based on 3 axes

수익성

산출 불가 (적자)

성장

Top 78%

밸류에이션

Top 1%

재무 안정

Top 66%

Index ⓘ	-	P/E ⓘ	-	EPS (ttm) ⓘ	-0.93	Insider Own ⓘ	20.61%	Shs Outstand ⓘ	5.6M	Perf Week ⓘ	2.71%
Market Cap ⓘ	0.03B	Forward P/E ⓘ	-	EPS next Y ⓘ	-	Insider Trans ⓘ	-	Shs Float ⓘ	4.5M	Perf Month ⓘ	21.18%
Enterprise Value ⓘ	0.03B	PEG ⓘ	-	EPS next Q ⓘ	-0.28	Inst Own ⓘ	8.82%	Short Float ⓘ	1.62%	Perf Quarter ⓘ	-37.98%
Income ⓘ	-0.00B	P/S ⓘ	71.02	EPS this Y ⓘ	-	Inst Trans ⓘ	-	Short Ratio ⓘ	0.52	Perf Half Y ⓘ	-31.67%
Sales ⓘ	0.00B	P/B ⓘ	6.26	EPS next 5Y ⓘ	-	ROA ⓘ	-27.66%	Short Interest ⓘ	0.07M	Perf YTD ⓘ	-28.2%
Book/sh ⓘ	0.79	P/C ⓘ	346.25	EPS past 3/5Y ⓘ	27.91% -72.14%	ROE ⓘ	-43.87%	52W High ⓘ	-44.33% ($8.84)	Perf Year ⓘ	43.73%
Cash/sh ⓘ	0.01	P/FCF ⓘ	-	Sales past 3/5Y ⓘ	68.99% -	ROIC ⓘ	-112.04%	52W Low ⓘ	57.69% ($3.12)	Perf 3Y ⓘ	16.31%
Dividend Est. ⓘ	-	EV/EBITDA ⓘ	-	EPS Y/Y TTM ⓘ	34.45%	Gross Margin ⓘ	-324.4%	Volatility(W/M) ⓘ	7.68% 9.33%	Perf 5Y ⓘ	-71.34%
Dividend TTM ⓘ	-	EV/Sales ⓘ	82.9	Sales Y/Y TTM ⓘ	61.11%	Oper. Margin ⓘ	-824.18%	ATR (14) ⓘ	0.45	Perf 10Y ⓘ	-
Dividend Ex-Date ⓘ	-	Quick Ratio ⓘ	0.03	EPS Q/Q ⓘ	-26.32%	Profit Margin ⓘ	-751.47%	RSI (14) ⓘ	52.14	Recom ⓘ	-
Dividend Gr. 3/5Y ⓘ	-	Current Ratio ⓘ	0.06	Sales Q/Q ⓘ	-56.41%	SMA20 ⓘ	4.13% ($4.72)	Beta ⓘ	1.26	Target Price ⓘ	-
Payout ⓘ	-	Debt/Eq ⓘ	1.85	Earnings ⓘ	2026/6/1	SMA50 ⓘ	-2.78% ($5.06)	Rel Volume ⓘ	0.09	Prev Close ⓘ	$4.68
Employees ⓘ	-	LT Debt/Eq ⓘ	0.04	EPS/Sales Surpr. ⓘ	2.69% -2.68%	SMA200 ⓘ	-25.72% ($6.62)	Avg Volume(3M) ⓘ	0.14M	Price ⓘ	$4.92
IPO ⓘ	2026/5/20	Option/Short ⓘ	No/Yes			Trades ⓘ	158	Volume ⓘ	13,030	Change ⓘ	5.13%

Quarterly earnings trend Quarterly earnings data is not yet available — foreign-listed companies (ADRs) only file annual reports with the U.S., and recently listed companies may not have filed their first quarterly report.

📊 Optimi Health Corp (OPTH) Investment Analysis

What kind of company is Optimi Health Corp?

옵티미 헬스(OPTH)

Healthcare · Drug Manufacturers - Specialty & Generic

Small-Cap — Low Volume, High Volatility

💊 Optimi Health (OPTH) is a Canada-based pharmaceutical manufacturer specializing in strict pharmaceutical-grade production of psychedelic medicines. It holds a relatively rare commercial-scale manufacturing capability for producing botanical psilocybin and MDMA legally for medical use, supplying these to regulated-permitted markets such as Australia and Canada.

Learn more about Optimi Health Corp →

Market Cap

$0.0B

Approx. KRW 0.0 trillion

⚖️ 0% of Samsung Electronics

Market Cap Rank5149

IPO2026/05/20

Current Price$4.92 ≈ 6,740원

NASD · Canada

Key Events

⏰ Upcoming events

🔔 Earnings release

The next release date has not been announced yet.

🎯 Ex-dividend date

No scheduled dividends

📜 Recent events

🔔 Earnings release 2026년 6월 1일 (월) · 장 마감 후 EPS +2.7% 매출 -2.7%

Is it profitable?

Both profitability & finances need caution

Review management risk carefully before investing

Profitability — How efficiently it makes money

Operating Margin

Profit kept from selling products and services (higher is better)

-824.2%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

Net Margin

Share of revenue left after taxes and interest are paid

-751.5%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

Gross Margin

Profit after subtracting raw-material costs only (signals product competitiveness)

-324.4%

✓ 부진

My positionBottom 25%

Low range Average High range

Drug Manufacturers - Specialty & Generic 초소형주 Median 26.6% · Bottom 10%

💡 제조업 30%, IT/소프트웨어 50% 이상이면 우수 (업종별 편차 큼)

ROE

Annual return earned on shareholders' equity (15%+ is strong)

-43.9%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

ROA

Annual earnings relative to total company assets

-27.7%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

ROIC

Return generated per dollar invested in the business

-112.0%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

Financial health — Debt & liquidity burden

Debt-to-Equity (D/E)

Debt relative to equity (lower is healthier)

1.85

✓ High debt

My positionBottom 25%

Low range Average High range

Drug Manufacturers - Specialty & Generic Median 0.36

💡 일반적으로 1.0 이하면 건전, 1.5까지는 무난 (금융·유틸·REIT는 구조적으로 높음)

Current Ratio

Liquid assets available to cover liabilities due within a year

0.06

✓ 위험

💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의

Quick Ratio

Liquid assets excluding inventory, available for immediate use

0.03

✓ 위험

💡 1.0 이상이면 안전, 0.5 미만이면 주의

* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Outlook data is insufficient

Analyst estimates and price targets have not been collected.

Did earnings meet expectations?

High Earnings Reliability

Beat estimates in 1 of the last 1 quarters

예상 상회

예상 부합

예상 하회

100%

상회 비율

+2.7%

평균 서프라이즈

2026.06.01

상회

+2.7%

💡 예상보다 높은 실적을 자주 내는 기업은 실적 신뢰도가 높다고 평가됩니다. 단, 애널리스트 기대치가 낮게 설정되었을 수도 있으니 절대 수치도 함께 봐야 합니다.

Is it growing?

Average Growth

Mid-range within the industry

📊 How much has it grown? (actual results)

Past 3-Year EPS

Actual average annual EPS growth over the past 3 years

+27.9%

양호

My positionMid-range

Low range Average High range

미분류 초소형주 Median 25.4% · Top 48%

Past 5-Year EPS

Actual average annual EPS growth over the past 5 years

-72.1%

매우 부진

My positionBottom 5%

Low range Average High range

미분류 초소형주 Median 14.6% · Bottom tier

⚡ Short-term momentum

QoQ Revenue

Revenue change from the previous quarter (short-term momentum)

-56.4%

부진

My positionBottom 25%

Low range Average High range

미분류 초소형주 Median -2.6% · Bottom 13%

* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.

New to investing terms? Look it up in the financial dictionary →

Has the stock risen over the long term?

Long-term weakness — -140%p below the market

OPTH -71.3% · S&P 500 +68.3%

Excess return vs. market (price-based, ex-dividends)

5-year basis

vs S&P 500

-139.7%p

Significantly behind the market

vs Health Care (XLV)

-95.8%p

Significantly behind the sector average

1-year basis

vs S&P 500

+27.7%p

ahead of the market

vs Health Care (XLV)

+24.0%p

ahead of the sector average

Rank among peers

5-year return Top 19% Based on 28 peers

1-year return Top among peers Based on 36 peers

Current position within 52-week range

Low (-57.7%p) High (-44.3%p)

Current price is 57.7% above the 52-week low and 44.3% below the 52-week high

Recent risk (last 45 trading days)

Max drawdown

-34.0%

Annualized volatility

117.7%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 46-day series

Price · Bollinger Bands · Ichimoku Cloud

close
BB Upper
BB Mid
BB Lower
Tenkan
Kijun
Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🟢

Current diagnosis · 2026-07-27

Uptrend zone

Current price $4.92 above the midline ($4.72). Normal upward flow.

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

🟡

Current diagnosis · 2026-07-27

Neutral zone — weak trend

MACD -0.058 · Signal -0.121 · Hist 0.062. Weak directional bias.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

🟢

Current diagnosis · 2026-07-27

Bullish zone

RSI 52.1 (above the neutral level of 50). Buying pressure leads, supporting a steady rise. Stoch %K is also 74.5.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

Pricier than peers in its industry

Pricey on Vs. Assets·Vs. Sales

💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.

🏢 Vs. Assets Pricey

🧾 Vs. Sales Pricey

🏢 Vs. Assets

PBR Price-to-Book Ratio

Price vs. the company's asset value — below 1 trades cheaper than assets

6.26x

✓ Very pricey

My positionBottom 5%

Low range Average High range

Drug Manufacturers - Specialty & Generic 초소형주 median 0.78x · Bottom 1% — expensive within the industry

💡 PBR 1 미만이면 청산가치 이하 (금융·제조업에서 특히 의미, IT는 낮은 비중)

🧾 Vs. Sales

PSR Price-to-Sales Ratio

Market cap vs. revenue — lower is cheaper relative to sales

71.02x

✓ Very pricey

My positionBottom 5%

Low range Average High range

Drug Manufacturers - Specialty & Generic 초소형주 median 1.82x · Bottom 1% — expensive within the industry

💡 PSR 2 이하 저평가, 10 초과면 고평가 (고성장 기업일 때만 정당화)

* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.

As of: Recent snapshot · Peer group: Drug Manufacturers - Specialty & Generic 초소형주

Who owns it?

Ownership is broadly stable

Short interest light 1.6% · Short interest up +0.7pp over last 31d

📈 Recent trading flow (6 months)

🧑‍💼 Insiders (executives & directors)

0.0%

Insiders little change

🏦 Institutions (funds & investors)

No trading data for Institutions

💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.

👥 Holdings composition

🏦 Institutions 8.8%

Retail-led

Healthcare 초소형주 Median 14.2%

🧑‍💼 Insiders 20.6%

Founder/management large holders (strong skin-in-the-game)

Healthcare 초소형주 Median 16.1%

👤 Retail investors (estimated) 70.6%

Everyone excluding institutions and insiders

Institutions Insiders Retail (est.)

📉 Short-selling metrics

Short ratio

1.6%

Low — limited short-side pressure

Healthcare 초소형주 Median 3.9%

Past 31 days 📈 +0.7%p increase

Short interest days to cover

0.5 days

Days needed to close short positions using average trading volume

🧮 Share count

Total shares outstanding 5.6M주

Float (tradable shares) 4.5M주

* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 31 days.

How much does it pay in dividends?

This company does not pay a dividend

It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)

Sorted by market cap, largest first

Stock	Market Cap	PER	PBR	ROE	Dividend Yield	Change
OPTH This Stock	$27.7M	-	6.3 ▼	-43.87% ▲	-	+5.1%
LLY	$1.13T	43.1 ▼	36.2 ▼	107.64% ▲	0.58% ▼	+0.1%
JNJ	$640.9B	30.8 ▼	7.5 ▼	25.74% ▲	2.02% ▲	+1.0%
ABBV	$453.9B	126.7 ▼	-	15221.82% ▲	2.67% ▲	-0.9%
UNH	$379.3B	26.9 ▼	3.9 ▼	12.49% ▲	2.16% ▲	-0.7%
MRK	$323.0B	36.8 ▼	7.0 ▼	18.97% ▲	2.5% ▲	-0.2%
Sector Avg	-	26.1	2.7	-48.83%	1.23%	-

FAQ

What kind of company is 옵티미 헬스(OPTH)?

옵티미 헬스(OPTH) belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.

What is the market cap of OPTH?

The market cap of OPTH is approximately $28M, ranking 5,149 within its sector.

What is the 52-week high and low for OPTH?

OPTH has recorded a 52-week high of $8.84 and a low of $3.12.

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.